CORAL GABLES, FL / ACCESSWIRE / October 6, 2017 / Here are 3 technology stocks that you should have on your watch-list during Friday's trading hours.
EnviroTechnologies International, Inc. (ETII) is a company that develops and markets green, natural, and organic products for diverse industries. Since the start of this trading week, ETII has seen a price per share increase of 29.82%, from lows on Monday (10/2) of $0.57 to intraday highs during Friday morning's trading session of $0.74.
In the company's most recent press release, they announced a new addition to their Scientific Advisory Board. The company appointed Bio-catalytic Surfactant expert Robert Chickerings to their board. Click Here for More Info.
LiNiu Technology Group (NASDAQ: LINU), a technology company that recently launched its electronic trading platform focused on the Chinese agricultural industry, saw a surge in its stock price during Friday morning's trading session. LINU price per share hiked 120.90%, from lows of $1.10 to intraday highs of $2.43 on Friday.
"We are pleased to announce that Mr. Robert Chickering joined our Scientific Advisory Council. He will be working with us in our ongoing efforts to commercially implement ETI's proprietary Activate™ Bio-catalytic Surfactant Products. Mr. Chickering has been in the forefront of identifying and qualifying the uses and benefits of Activate™ related non-toxic and natural surfactants. He has been a champion of environmentally responsible products and procedures for everything from cleaning oil field equipment, to treating and reclaiming contaminated wetlands and shorelines polluted by oil spills," stated John Hopkins, ETI's President. Click Here for More Info.
TearLab Corporation (TEAR) continued to advance during Friday morning's trading session after jumping 27.85% during Thursday's trading session, from lows of $1.40 to intraday highs of $1.79. On Friday morning, the stock gained another 13.45%, from daily lows of $1.71 to an intraday high of $1.94. The company develops and markets lab-on-a-chip technologies that enable eye care doctors to enhance their standard of care. In the company's last press release, they announced the release of their 2018-2020 preliminary rates for clinical diagnostic laboratory tests.
"We are pleased that the CMS reimbursement rate will remain stable as a result of the PAMA review for both our current osmolarity test, as well as for the inflammatory biomarkers we expect to be approved with the TearLab Discovery™ System. We believe this supports the growing importance of dry eye disease and the value our test delivers to physicians and patients as an aid in the diagnosis and management of dry eye disease," stated Seph Jensen, Chairman and CEO of TearLab. Click Here for More Info.
For free, up-to-the-minute financial news updates, text keyword HFNEWS to 474747.
HeraldFinance.com ("HF") is owned by MAD Media Publishing LLC, a Nevada corporation. HF produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. HF has not been compensated: an affiliate company of HR, Midam Ventures, LLC has been compensated $150,000.00 by a non affiliated third party for a period beginning October 2, 2017 and ending November. 2, 2017 to publicly disseminate information about ETII. We own zero shares.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither HF nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.HeraldFinance.com/.
HF, the Author, and the Reviewer (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect, or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise, arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
SOURCE: Herald Finance